A €9.1 Billion Dividend Fund Inches Toward Its Record as a Lyme Disease Vaccine Clears a Key Hurdle
Published on 08/14/2026 at 15:32 | Redaktion boerse-global.de
The VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF is sitting just a whisker away from its 52-week peak, and one of its heavyweight holdings just got a regulatory shot in the arm.
The fund closed Thursday at €55.46, a mere 0.4 percent below the €55.66 high it touched in early August. Since the start of the year, it has climbed 15 percent, with a trailing twelve-month gain of 25 percent — evidence that income-focused strategies haven't had to sacrifice capital appreciation in the current environment.
A Regulatory Win for a Core Holding
The latest tailwind comes from Pfizer, which accounts for roughly 3.85 percent of the portfolio and ranks among the fund's five largest positions. On August 14, the European Medicines Agency validated the marketing authorization application for a Lyme disease vaccine candidate developed jointly with Valneva. The regulatory green light marks a tangible step forward for the pharma giant and reinforces the defensive character of the fund's healthcare sleeve, which balances out more cyclical holdings.
The ETF's top positions span a mix of sectors, including Verizon Communications, HSBC Holdings, Nestlé, and Shell — a lineup that underscores the strategy's tilt toward established, cash-generative businesses.
Nine Billion and Counting
VanEck ETFs N.V. published official net asset figures on August 13, confirming the fund's scale. Based on closing data from the prior day, total assets stand at roughly €9.14 billion, with 166.15 million shares outstanding and a net asset value of €55.0266 per unit. That scale makes it one of the more prominent names in the dividend-focused UCITS space.
The fund tracks the Morningstar Developed Markets Large Cap Dividend Leaders Screened Select Index, which screens for payout stability, applies ESG risk checks, and adheres to UN Global Compact principles. The goal is to exclude companies embroiled in major controversies while still capturing hefty distributions. The result is a portfolio concentrated in financials, energy, and healthcare.
Yield That Pulls Its Weight
For income-oriented investors, the headline number is the expected dividend yield of 5.86 percent as of August 9, with the most recent distribution coming in at €0.81 per share. Payouts arrive quarterly, with the next one scheduled for September 10.
That yield is a central draw, but the fund's cost structure also bears scrutiny. The total expense ratio sits at 0.38 percent — cheaper than the iShares STOXX Global Select Dividend 100 UCITS ETF's 0.46 percent, though pricier than the Vanguard FTSE All-World High Dividend Yield UCITS ETF's 0.29 percent. The trade-off: VanEck fully replicates the underlying index with physical holdings rather than relying on optimized sampling or synthetic methods, which tends to push costs slightly higher but ensures precise tracking.
Following the semi-annual rebalancing in June, financials now account for more than 40 percent of net assets — by far the largest allocation. Geographically, Europe dominates, with the UK, France, and Italy leading the way, supplemented by a solid US presence.
Technical Signals Point Upward
On the chart, the relative strength index stands at 66.9, approaching but not yet breaching the overbought threshold of 70. Meanwhile, annualized 30-day volatility sits at a modest 7.8 percent — a relatively calm reading for an equity ETF.
Should the fund push through the €55.66 ceiling, it would mark a fresh 52-week high. Whether demand for high-dividend stocks remains strong enough to carry it there is the question for the coming sessions — but with a regulatory win for a top holding, a hefty yield, and momentum on its side, the pieces appear to be in place.
Ad
VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF Stock: New Analysis - 14 August
Fresh VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Read our updated VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF analysis...
